Home/Pipeline/Remyelination Drug Discovery

Remyelination Drug Discovery

Multiple Sclerosis

Pre-clinicalActive

Key Facts

Indication

Multiple Sclerosis

Phase

Pre-clinical

Status

Active

Company

Artificial Axon Labs

About Artificial Axon Labs

Artificial Axon Labs is an early-stage biotech founded in 2021, originating from MIT research, that is building a novel drug discovery platform. The company's core innovation is the 'Artificial Axons' assay, which uses advanced 3D printing to create axon-like structures, enabling direct, high-throughput quantification of myelination by human cells in a brain-mimetic environment. This platform aims to overcome the limitations of animal models and traditional 2D assays to identify promising drug candidates for demyelinating diseases like MS. The company is pre-revenue, has won several grants and awards, and is advancing its platform validation and early drug discovery efforts.

View full company profile

Therapeutic Areas

Multiple Sclerosis Neurodegenerative Diseases

Other Multiple Sclerosis Drugs

Drug	Company	Phase	Status
Mimotopes-003	Mimotopes	Preclinical	Active
SPU-16	Silo Pharma	Preclinical	Research
Electroceutical® Therapy	Endonovo Therapeutics	Research	Active
IMX39	Imunexus Therapeutics	Preclinical	Active
BTK allosteric inhibitor	Acellera	Pre-clinical	Early Hit
CLS12311	Cellerys	Phase 2	Active
Interferon-beta variants	Heligenics	Pre-clinical	Active
G-NK cells	Indapta Therapeutics	Phase 1	Active
MS Biomarker Research	Rune Labs	Research	Active
AVT001	Avotres	Phase 2b	Active
Undisclosed MS Program	Astoria Biologica	Pre-clinical	Active
PV-3212	Provid Pharma	Pre-clinical	Active